Business Wire Industry News

Wednesday, June 18, 2025

Satellos Bioscience Shareholders Elect Two New Board Members

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors. “I am so excited to welcome Dr. Loew-Friedrich and Dr. Ho to our Board at this pivotal time,” said Frank Gleeson, Satellos co-founder and CEO. “We

Wednesday, June 18, 2025

Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special Meeting of Shareholders held June 18, 2025 (the “Meeting”). Satellos is pleased to announce that all the nominees listed in the management information circular dated May 12, 2025 (the “Circular”), were elect

Wednesday, June 18, 2025

MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant

BURLINGTON, Mass.--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced Neoclease as the winner of the 2025 North American Advance Biotech Grant. The Boston-based biotech startup develops AI-designed gene editing therapies for Parkinson’s disease. “We’re committed to empowering biotech innovators who are advancing transformative modalities like gene editing,” said Sebastián Arana,

Tuesday, June 17, 2025

World’s First Wearable Doppler Ultrasound Patch Expands to East Coast to Enhance Patient Safety at The Mount Sinai Hospital

LOS ANGELES--(BUSINESS WIRE)-- #flopatch--Flosonics Medical, the leader in wearable ultrasound for critical care, today announced that The Mount Sinai Hospital has adopted FloPatch, the first wireless Doppler ultrasound device, in its surgical and transplant intensive care units. This milestone marks the company’s first East Coast deployment, expanding its U.S. footprint and reinforcing growing demand for real-time, individualized fluid management in ICUs. FloPatch is an FDA-cleared, non-invasive wearable

Tuesday, June 17, 2025

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including Amy Pott, Chief Global Commercialization Officer, with a grant date of June 16, 2025. The inducement award for Ms. Pott consists of a non-qualified stock option to purchase an aggregate 400,000 of the Company's common shares. The inducement awards fo

Tuesday, June 17, 2025

Echo and Northern Fitness Announce Strategic Distribution Partnership

SALT LAKE CITY & TORONTO--(BUSINESS WIRE)--Echo, the category leader in hydrogen-based health solutions, has entered into an exclusive distribution partnership with Northern Fitness, one of Canada’s premier fitness retailers. This new collaboration will expand Echo’s reach into the Canadian market, offering consumers access to its innovative hydrogen-based wellness products designed to promote health and vitality. Northern Fitness will begin distributing Echo’s flagship products, including the

Tuesday, June 17, 2025

Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing

BEIJING--(BUSINESS WIRE)--In response to Harbour BioMed’s recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement: Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen’s proprietary genome editing technologies. Its technical principles, design strategy,

Monday, June 16, 2025

Driving Sector Growth Through Partnership: BIOQuébec and Bioscience Association Manitoba (BAM) Sign Memorandum of Understanding

LAVAL, Québec & WINNIPEG, Manitoba--(BUSINESS WIRE)--BIOQuébec and Bioscience Association Manitoba (BAM) are proud to announce the signing of a Memorandum of Understanding (MOU) that establishes a partnership between two of Canada’s leading life sciences organizations. This marks an important step toward a more integrated and competitive Canadian life sciences landscape, built on regional strengths and shared innovation goals. The MOU is intended to deepen ties between Quebec and Manitoba’s vib

Monday, June 16, 2025

Enveric Biosciences Announces Participation in 2025 BIO International Convention

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. During the conference, CEO and Director of Enveric, Joseph Tucker, Ph.D., will conduct one

Monday, June 16, 2025

Conscience Announces Results of CACHE Challenge #4, Targeting Cancer Immunotherapy

TORONTO--(BUSINESS WIRE)--Conscience, a non-profit that uses open science and true collaboration to enable drug discovery and development where market solutions are limited, is pleased to announce the results of its fourth CACHE (Critical Assessment of Computational Hit-Finding Experiments) Challenge, and the identification of a chemically novel and bioactive molecule. CACHE Challenge #4 focused on the difficult task of identifying novel molecules that bind to CBLB, a cancer immunotherapy targe

Monday, June 16, 2025

Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las Vegas, Nevada. The PPMD Annual Conference brings together families, researchers, clinicians, and companies committed to impr

Friday, June 13, 2025

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today provided a corporate update. “It is especially gratifying that at a time when we are advancing our clinical pipeline programs, with our lead program CYB003 in Phase 3 development, the path toward approval and eventua

Thursday, June 12, 2025

Pluristyx Launches PluriForm™ Organoid Kit, Slashing Weeks Off Organoid Development Timelines

SEATTLE--(BUSINESS WIRE)--Pluristyx, a leading provider of tools and services for cell product development, today announced the launch of their first-of-its-kind PluriForm™ Organoid Kit, a turnkey solution to eliminate critical bottlenecks in organoid research and allow scientists to rapidly and reliably make pluripotent aggregates using quality-assured, induced pluripotent stem cells (iPSCs). The kit saves weeks of cell culture work and eliminates variability in organoid manufacturing, allowin

Thursday, June 12, 2025

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. “We have seen strong enrollment in the pivotal cohort of our LEGEND study,” said Ron Cooper, Chief Executive Officer of enGene. “This positions us to stay on track for our planned trial updates across all cohorts in the second

Thursday, June 12, 2025

NEUPATH HEALTH ANNOUNCES VOTING RESULTS FROM THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 11, 2025 and the grant of stock options (“Options”) and restricted share units (“RSUs”). All figures are in Canadian dollars, unless otherwise noted. The results of the director elections wer

Thursday, June 12, 2025

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference, taking place June 16-17, 2025. Mr. Drysdale’